[Caution] hepatic endpoints need biopsy data, not an ALT screenshot
Something I keep coming back to: hepatic endpoints need biopsy data, not an ALT screenshot.
Sent a vial to Janoshik because there was nothing on file. 98.4% against a claimed 97.5%. First entry for this compound in my own log.
The escalation schedules in the published protocols are slow and deliberate, and the tolerability tables show why. That is a description of the trials rather than a suggestion for anybody.
Read the phase 2 hepatic paper properly and the endpoint definitions were more interesting than the headline response rate.
Research-use-only material is not approved for human use and nothing here should be read as a recommendation to use it.
best — the order this archive was captured in
Nothing containing this compound is approved anywhere. Research-use-only material is not approved for human use.
Independent purity results for this compound are very sparse across the whole site, which means any impression about consistency is built on almost nothing.
That figure is from the obesity programme, and this thread is about the hepatic one.
How fast was the escalation in that protocol?
Independent result logged. There are almost none for this compound, so it is genuinely valuable.
the weight numbers are secondary to what this is being developed for
[deleted]
research material is not approved for human use, which is why the clinical record here is thin
Went slowly because everything published describes a deliberate escalation. That is the extent of what I will say about it.